Exposure-response analysis of rilotumumab in gastric cancer: the role of tumour MET expression

BACKGROUND: Rilotumumab, an investigational, monoclonal antibody, inhibits MET-mediated signalling. In a randomized phase 2 trial of rilotumumab±epirubicin/cisplatin/capecitabine in gastric or oesophagogastric junction cancer, patients receiving rilotumumab showed a trend towards improved survival,...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Br J Cancer
Main Authors: Zhu, M, Tang, R, Doshi, S, Oliner, K S, Dubey, S, Jiang, Y, Donehower, R C, Iveson, T, Loh, E Y, Zhang, Y
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 2015
Fag:
Clinical Study
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4453660/
https://ncbi.nlm.nih.gov/pubmed/25584489
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bjc.2014.649
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker